Talk:List of investigational sexual dysfunction drugs
Appearance
This is the talk page for discussing improvements to the List of investigational sexual dysfunction drugs article. This is not a forum for general discussion of the article's subject. |
Article policies
|
Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL |
This article is rated List-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||||||||||||||||
|
Cleanup of drugs needed
[edit]Throughout the article, drugs are lumped together and then their mechanisms of action (MOA) are described ambiguously. For example, bupropion and trazodone are lumped together, and then a number of MOAs are listed. It is not clear why these two are lumped together, because they are drugs from completely different categories. Further, it is unclear which MOA corresponds with which drug.
Bupropion/trazodone (S1P-104, S1P-205, Lorexys, Orexa) – norepinephrine reuptake inhibitor, nicotinic acetylcholine receptor antagonist, 5-HT2A receptor antagonist, α1-adrenergic receptor antagonist, weak serotonin reuptake inhibitor[12]
Cleanup is needed to avoid reader misunderstandings. --1000Faces (talk) 05:54, 13 June 2020 (UTC)
Categories:
- List-Class List articles
- Unknown-importance List articles
- WikiProject Lists articles
- List-Class pharmacology articles
- Unknown-importance pharmacology articles
- WikiProject Pharmacology articles
- List-Class medicine articles
- Mid-importance medicine articles
- List-Class psychiatry articles
- Mid-importance psychiatry articles
- Psychiatry task force articles
- All WikiProject Medicine pages